The DOI matches its Crossref record.
A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus
Open accessAbstract
Esophageal adenocarcinoma risk in Barrett's esophagus (BE) is increased 30- to 125-fold versus the general population. Among all BE patients, however, neoplastic progression occurs only once per 200 patient-years. Molecular biomarkers are therefore needed to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression. We therefore performed a retrospective, multicenter, double-blinded validation study of eight BE progression prediction methylation biomarkers. Progression or nonprogression were determined at 2 years (tier 1) and 4 years (tier 2). Methylation was assayed in 145 nonprogressors and 50 progressors using real-time quantitative methylation-specific PCR. Progressors were significantly older than nonprogressors (70.6 versus 62.5 years; P < 0.001). We evaluated a linear combination of the eight markers, using coefficients from a multivariate logistic regression analysis. Areas under the ROC curve (AUC) were high in the 2-year, 4-year, and combined data models (0.843, 0.829, and 0.840; P < 0.001, <0.001, and <0.001, respectively). In addition, even after rigorous overfitting correction, the incremental AUCs contributed by panels based on the 8 markers plus age versus age alone were substantial (Δ-AUC = 0.152, 0.114, and 0.118, respectively) in all 3 models. A methylation biomarker–based panel to predict neoplastic progression in BE has potential clinical value in improving both the efficiency of surveillance endoscopy and the early detection of neoplasia. [Cancer Res 2009;69(10):4112–5]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
DNA methylation profiles in cancer diagnosis and therapeutics
Pan, Y., Liu, G., Zhou, F., Su, B., & Li, Y. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-017-0467-0 · Cited by 373
Genomic copy number predicts esophageal cancer years before transformation
Killcoyne, S., Gregson, E., Wedge, D. C., Woodcock, D. J., Eldridge, M. D., de la Rue, R., Miremadi, A., Abbas, S., Blasko, A., Kosmidou, C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1033-y · Cited by 149
Metadata
- Authors
- Jin, Z., Cheng, Y., Gu, W., Zheng, Y., Sato, F., Mori, Y., Olaru, A. V., Paun, B. C., Yang, J., Kan, T., Ito, T., Hamilton, J. P., Selaru, F. M., Agarwal, R., David, S., Abraham, J. M., Wolfsen, H. C., Wallace, M. B., Shaheen, N. J., Washington, K., Wang, J., Canto, M. I., Bhattacharyya, A., Nelson, M. A., Wagner, P. D., Romero, Y., Wang, K. K., Feng, Z., Sampliner, R. E., & Meltzer, S. J.
- Venue
- Cancer Research
- Published
- 2009-05-15
- Volume
- 69
- Issue
- 10
- Pages
- 4112-4115
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2056327333
- Cited by
- 222
- References
- 0
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-0028
- The paper
- Jin, Z., Cheng, Y., Gu, W., Zheng, Y., Sato, F., Mori, Y., Olaru, A. V., Paun, B. C., Yang, J., Kan, T., Ito, T., Hamilton, J. P., Selaru, F. M., Agarwal, R., David, S., Abraham, J. M., Wolfsen, H. C., Wallace, M. B., Shaheen, N. J., . . . Meltzer, S. J. (2009). A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-0028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.